PRODUCT PIPELINE

AVONEX^® (Interferon beta-1a) is used worldwide, with more than 135,000 patients on therapy, as a treatment for relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is also approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS.

AVONEX^® (Interferon beta-1a) is used worldwide, with more than 135,000 patients on therapy, as a treatment for relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX is also approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS.

TYSABRI is being developed and co-marketed under a collaboration agreement with Elan.

Fampridine is an investigational oral, prolonged-release formulation of 4-aminopyridine, that has been developed to improve walking ability in adult patients with multiple sclerosis (MS). Studies have shown that fampridine can increase conduction velocity along damaged nerves, which may result in improved neurological function. This compound is approved in the US (where it is known as dalfampridine) and is being commercialized outside of the US by Biogen Idec under a licensing agreement with Acorda Therapeutics.

PEGylated Interferon beta-1a is a chemically modified version of interferon beta-1a, designed to increase half-life and systemic exposure of the protein.

Small molecule immune modulator, oral formation. Acquired with Fumapharm purchase.

Humanized antibody specific for IL2 receptor. Daclizumab is being developed under a collaboration agreement with PDL BioPharma.

Novel oral neuroprotective therapy. KNS-760704 is being developed under a licensing agreement with Knopp Neurosciences.

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Novel neurotrophic protein in GDNF family. Neublastin is being developed under a licensing agreement with NsGene.

Anti-LINGO 1 is being investigated for use in multiple sclerosis.

Rituxanis being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

RITUXAN (Rituximab) is in development for the treatment of Chronic Lymphocytic Leukemia, and is not currently approved for this indication. Rituxan is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is being developed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

PRIMATIZED monoclonal antibody specific for CD80.

Novel small molecule HSP90 inhibitors. Acquired with Conforma purchase.

Human monoclonal antibody specific for IGF-1R.

Chimeric monocloncal antibody specifc for VLA5 (alpha5beta1 integrin). M200 is being developed under a collaboration agreement with PDL BioPharma.

Cripto-targeting humanized monoclonal antibody with ImmunoGen's cell-killing agent, DM4, attached.

Rituxan is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

FUMADERM is an oral product containing fumaric acid esters, and was approved in Germany in 1994 for treatment of severe psoriasis. Acquired with the Fumapharm purchase.

TYSABRI is being developed and co-marketed under a collaboration agreement with Elan.

RITUXAN (Rituximab) is in development for the treatment of ANCA Associated Vasculitis, and is not currently approved for this indication. Rituxan is being developed and co-marketed under a collaboration agreement with Genentech, a wholly-owned member of the Roche Group.

Humanized monoclonal antibody specific for TWEAK.

Novel humanized anti-CD40L Fab-PEG being developed with UCB.

Long-acting factor IX fusion protein for the treatment of hemophilia B. Acquired with Syntonix transaction. Biogen Idec and Biovitrum are working in collaboration on co-development.

Long-acting factor VIII fusion protein for the treatment of hemophilia A. Acquired with Syntonix transaction. Biogen Idec and Biovitrum are working in collaboration on co-development.

Lixivaptan is an oral, selective V2 vasopressin receptor antagonist. Lixivaptan is being developed under a collaboration agreement with Cardiokine.